Department: Division of General Psychiatry
Head: Lanzenberger, Rupert, Univ.-Prof. Priv.-Doz. Dr.med.
Research Area
Molecular Psychiatry, Neuroimaging (Positron Emission Tomography, Functional Magnetic Resonance Imaging), Neuropsychopharmacology
Description
The integration of functional, structural and molecular neuroimaging expertise plays a pivotal role in clinical neurosciences and supports the assessment of changes and alterations in the diseased and healthy human brain in vivo. Hence, our main research areas comprise multimodal neuroimaging using PET, PET/MR, structural and functional MRI as well as connectivity assessments in both psychiatric and neurological patients and healthy subjects. This extends to neuroimaging in psychopharmacology, psychoneuroendocrinology including gender medicine, cognitive neuroscience, imaging genetics (genotyping/GWAS, epigenetics/EWAS, gene expression) and experimental neuronuclear medicine. Currently, we are focused on research within the monoaminergic neurotransmitter systems and are investigating pharmacological effects on the serotonin and norepinephrin transporters, the main serotonergic receptor subtypes, and enzymes such as monoamine oxidase A, and task-specific brain activation. New methodological advancements in multimodal neuroimaging combining pharmacological MRI (phMRI) and PET further allow for the evaluation of drug effects in the brain of healthy subjects and patients. Hence, the combination of molecular and functional imaging data may reveal novel information regarding relationship between neurochemical, structural and functional alterations in psychiatric and neurological disorders. For details see: http://www.meduniwien.ac.at/neuroimaging/
Members
Selected Publications of Principle Investigator
- Lanzenberger R, Baldinger P, Hahn A, Ungersboeck J, Mitterhauser M, Winkler D, Micskei Z, Stein P, Karanikas G, Wadsak W, Kasper S, Frey R (2013) Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET Mol Psychiatry, 18 (1): 93-100
- Hahn A, Wadsak W, Windischberger C, Baldinger P, Hoflich A, Losak J, Nics L, Philippe C, Kranz G, Kraus C, Mitterhauser M, Karanikas G, Kasper S, Lanzenberger R (2012) Differential modulation of the default mode network via serotonin-1A receptors PNAS, 109 (7): 2619-2624
- Savli M, Bauer A, Mitterhauser M, Ding Y, Hahn A, Kroll T, Neumeister A, Haeusler D, Ungersboeck J, Henry S, Isfahani S, Rattay F, Wadsak W, Kasper S, Lanzenberger R (2012) Normative database of the serotonergic system in healthy subjects using multi-tracer PET Neuroimage, 63 (1): 447-459
- Spindelegger C, Lanzenberger R, Wadsak W, Mien L, Stein P, Mitterhauser M, Moser U, Holik A, Pezawas L, Kletter K, Kasper S (2009) Influence of escitalopram treatment on 5-HT1A receptor binding in limbic regions in patients with anxiety disorders Mol Psychiatry, 14 (11): 1040-1050
- Lanzenberger R, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien LK, Holik A, Attarbaschi T, Mossaheb N, Sacher J, Geiss-Granadia T, Kletter K, Kasper S, Tauscher J. (2007) Reduced Serotonin-1A Receptor Binding in Social Anxiety Disorder. Biol Psychiatry, 61(9): 1081-9